Description
Guardant Health’s 70 Million-Patient Breakthrough — Shield Is Scaling Fast!
Guardant Health reported its second quarter 2026 financial results highlighting broad-based growth across all key segments: Oncology, Biopharma & Data, and Screening. Total revenue reached $335 million, up 44% year-over-year, with Oncology revenue at $219 million (38% growth), Biopharma & Data at $61 million (9% growth), and Screening revenue rising significantly to $53 million from $15 million a year ago. The company demonstrated accelerated test volume growth, particularly in its Oncology business, where volumes increased 63% year-over-year to approximately 104,000 tests, supported by expansions in products such as Guardant360 Liquid (over 30% volume growth), Guardant360 Tissue, and Reveal, the latter growing over 100% driven by minimal residual disease (MRD) and therapy monitoring adoption. Guardant360 Liquid CDx received FDA approval during the quarter, marking an important regulatory milestone.
